CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Christoph Zielinski
Honoraria - Bristol-Myers Squibb
Sabine Maier
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Veerle de Pril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Justin P. Fairchild
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jean-Marie Cuillerot
Employment or Leadership Position - Bristol-Myers Squibb
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer; Roche